Look who popped into the GU Cast studio this week for a chat about where we are going next with radioligand therapy (RLT) for prostate cancer! Professors Oliver Sartor (Mayo Clinic, Rochester) and Michael Hofman (Peter Mac, Melbourne), are two of the world's most pre-eminent experts in the world of RLT for prostate cancer. They were each respectively PIs  on the VISION and TheraP RCTs published in NEJM and Lancet in 2021, and both have many ongoing trials in RLT for prostate cancer. 
We hear in which stages of prostate cancer LuPSMA is next likely to be approved, and some discussion about exciting trials soon to read out. We also discuss other RLTs including actinium and terbium, combinations, imaging technology for patient selection, AI, and the word "cure" even gets a mention. A very entertaining and exciting discussion with two of the best in the business. 
Your regular hosts are Professor Declan Murphy and Dr Renu Eapen, Urologists at Peter MacCallum Cancer Centre, Melbourne.

This is a Themed Podcast supported by our Silver Partners, Novartis. 

Even better on our YouTube channel

Links:
Michael's paper in the Journal of Nuclear Medicine:"The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics"